Back to Search
Start Over
Thymopoietin pentapeptide treatment of primary immunodeficiencies.
- Source :
-
Lancet (London, England) [Lancet] 1983 Mar 12; Vol. 1 (8324), pp. 551-4. - Publication Year :
- 1983
-
Abstract
- 26 patients with primary immunodeficiencies (3 infants with severe combined immunodeficiency [SCID] 3 with DiGeorge syndrome, 6 with T-cell defect or SCID with B cells, 4 with common variable hypogammaglobulinaemia and associated T-cell defect, 5 with ataxia-telangiectasia, and 5 with hyper-IgE syndrome) were treated with thymopoietin pentapeptide (TP-5) at a dose of 0 . 5 mg/kg daily for 2 weeks and then 3 times a week at 0 . 5 mg/kg for 10 weeks, 3 patients with DiGeorge syndrome and 3 with primary T-cell defect demonstrated pronounced clinical and immunological improvement during treatment. None of the patients with SCID and 3 of 6 patients with SCID with B cells or primary T-cell defect showed any clinical or immunological changes during therapy. In 5 patients with ataxia-telangiectasia clinical manifestations and immunological tests were unchanged by TP-5. Abnormality of T cells in cases of hyper-IgE syndrome was not corrected by TP-5 treatment.
- Subjects :
- Adolescent
Adult
Agammaglobulinemia drug therapy
Ataxia Telangiectasia drug therapy
Child
Child, Preschool
DiGeorge Syndrome drug therapy
Female
Hormones administration & dosage
Humans
Immunity, Cellular
Immunoglobulin E immunology
Infant
Male
Peptide Fragments administration & dosage
T-Lymphocytes immunology
Thymopentin
Thymopoietins administration & dosage
Hormones therapeutic use
Immunologic Deficiency Syndromes drug therapy
Peptide Fragments therapeutic use
Thymopoietins therapeutic use
Thymus Hormones therapeutic use
Subjects
Details
- Language :
- English
- ISSN :
- 0140-6736
- Volume :
- 1
- Issue :
- 8324
- Database :
- MEDLINE
- Journal :
- Lancet (London, England)
- Publication Type :
- Academic Journal
- Accession number :
- 6131256
- Full Text :
- https://doi.org/10.1016/s0140-6736(83)92810-6